? CANDIDATE: Steven M. Rowe, MD MSPH is committed to a career in academic pulmonology as a translational scientist focused on cystic fibrosis (CF) and other airways diseases. This proposal is intended to familiarize Dr. Rowe with the design and conduct of leading edge biomedical science in a closely mentored research environment. ? SPONSORS: Eric Sorscher, MD (Director, UAB CF Research Center) is a national leader in CF research and has extensive experience mentoring physician-scientists. JP Clancy, MD has worked daily with Dr. Rowe in related research projects and will provide instruction regarding the operation of a national multicenter CF clinical trial. George Howard, PhD will direct Dr. Rowe's advanced training in biostatistics. ? ENVIRONMENT: UAB is well suited to provide translational research training, including state-of-the-art research facilities and excellent career development resources. ? RESEARCH: CF caused by premature stop mutations results in the production of little or no functional cystic fibrosis transmembrane conductance regulator (CFTR). Certain small molecules have the capacity to reduce the fidelity of nonsense allele recognition, leading to translational readthrough of otherwise truncated CFTR and synthesis of full-length, active protein. This strategy has been successfully employed to correct CFTR function in CF subjects in vivo. A better understanding of mechanisms of action and investigation of more potent agents is required to advance this new treatment strategy. We will study the effects of stop mutation susceptibility to translational readthrough, and evaluate the importance of mRNA stability in this process. PTC124, a new compound that confers very potent stop suppression, will be evaluated in vitro and in a clinical trial. Successful completion of this project will define the potential role of nonsense codon suppression as a future CF therapy. ? LAY STATEMENT: Correcting premature stop mutations could improve or cure patients with CF and other genetic diseases caused by stop mutations. We propose to study this approach in the laboratory and in a clinical trial using a new, very active compound named PTC124. Results will help determine whether this treatment strategy can be used to treat individuals with CF and other inherited diseases. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23DK075788-02
Application #
7250222
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2006-07-01
Project End
2011-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
2
Fiscal Year
2007
Total Cost
$127,764
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Rowe, Steven M; Liu, Bo; Hill, Aubrey et al. (2013) Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One 8:e66955
Rowe, Steven M; Reeves, Ginger; Hathorne, Heather et al. (2013) Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis. Chest 144:200-207
Troxler, Robert Bradley; Hoover, Wynton C; Britton, LaCrecia J et al. (2012) Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis. Pediatr Pulmonol 47:1113-22
Clancy, J P; Rowe, Steven M; Accurso, Frank J et al. (2012) Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67:12-8
McClure, Michelle; DeLucas, Lawrence J; Wilson, Landon et al. (2012) Purification of CFTR for mass spectrometry analysis: identification of palmitoylation and other post-translational modifications. Protein Eng Des Sel 25:7-14
Sloane, Peter A; Shastry, Suresh; Wilhelm, Andrew et al. (2012) A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One 7:e39809
Fu, Lianwu; Rab, Andras; Tang, Li Ping et al. (2012) Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulator. Biochem J 441:633-43
Zhang, Shaoyan; Smith, Nicholas; Schuster, Daniel et al. (2011) Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: therapeutic implications for chronic rhinosinusitis. Am J Rhinol Allergy 25:307-12
Pyle, Louise C; Ehrhardt, Annette; Mitchell, Lisa High et al. (2011) Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators. Am J Physiol Lung Cell Mol Physiol 301:L587-97
Ramsey, Bonnie W; Davies, Jane; McElvaney, N Gerard et al. (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:1663-72

Showing the most recent 10 out of 26 publications